Intravesical hyaluronic acid – effective option in the treatment of hemorrhagic cystitis
S.P. Pasechnikov, MD, Professor, Head of Department of Urology at Bogomolets National Medical University, Head of Department of Inflammatory Diseases of the Government Institution "Institute of Urology of the National Academy of Medical Sciences of Ukraine"
V.N. Shilo, PhD, Head of Department of Urology of the Municipal Enterprise "Cherkasy Regional Hospital of Cherkasy Regional Council"
Hemorrhagic cystitis – an inflammatory disease of the bladder with a complex etiology. The frequency of this pathology has increased substantially due to the increase in the number of patients undergoing radiation therapy for malignant neoplasms of the pelvic organs. The development of rational treatment of hemorrhagic cystitis is a difficult problem. Given the pathogenetic basis of disease, it is assumed that the optimal methods of treatment should be aimed at the regeneration of glycosaminoglycan mucosal layer of the bladder. The article presents the results of a study of effectiveness of intravesical instillation of hyaluronic acid in the treatment of hemorrhagic cystitis.
Keywords: hemorrhagic cystitis, hyaluronic acid, radiotherapy.
Avant d'utiliser le médicament proposé sur ce site d'information il est strictement recommendé de consulter votre médecin et prendre connaissance de cette notice.
L'information sur le médicament destiné à l'activité médicale des spécialistes en protection de la santé. INSTYLAN 0,16% est un gel transparent, sans couleurs, contenant l'acide hyaluronique d'origine non animale, stéril avec un ph physiologique.
INSTYLAN 0,16% a une approbation de la ІІa classe du produit à destination médicale. Sertificat de conformité de l'Union européenne. Numéro d'enregistrement: DD 60107286 0001. Fabricant: Diaco Biofarmaceutici S.R.L. Via Flavia 124, 34147, Trieste, Italy. E-mail: info@diaco.it. www.diaco.it.
